Immunomodulatory activity of mesenchymal stem cells

Current Stem Cell Research and Therapy

Volumn 6, Issue 4, 2011, Pages 297-316

  Kaplan, Johanne M ^a   Youd, Michele E ^a   Lodie, Tracey A ^a  

^a GENZYME CORPORATION   (United States)

Author keywords

Autoimmunity; Diabetes; Graft versus host disease; Immunomodulation; Lupus; Mesenchymal stem cell

Indexed keywords

CORTICOSTEROID;

ADIPOCYTE; ALLERGIC ENCEPHALOMYELITIS; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIGEN PRESENTING CELL; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; B LYMPHOCYTE; CARTILAGE CELL; CELL ACTIVITY; CELL DIFFERENTIATION; CELL LINEAGE; CELL MATURATION; CROHN DISEASE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DOWN REGULATION; ENTERITIS; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNE SYSTEM; IMMUNOMODULATION; IMMUNOREGULATION; IN VITRO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOCYTE PROLIFERATION; MACROPHAGE; MACROPHAGE FUNCTION; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; NONHUMAN; OSTEOCYTE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; TISSUE INJURY; TISSUE REPAIR;

EID: 80055119541     PISSN: 1574888X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488811797904353     Document Type: Article

References (199)

1. Friedenstein AJ, Gorskaja JF, Kulagina NN. Fibroblast precursors in normal and irradiated mouse hematopoietic organs. Exp Hematol 1976; 4(5): 267-74.
2. Dazzi F, Ramasamy R, Glennie S, Jones SP, Roberts I. The role of mesenchymal stem cells in haemopoiesis. Blood Reviews 2006; 20(3): 161-71.
3. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284(5411): 143-7.
4. Hoogduijn MJ, Crop MJ, Peeters AM, et al. Human heart, spleen, and perirenal fat-derived mesenchymal stem cells have immuno-modulatory capacities. Stem cells dev 2007; 16(4): 597-604.
5. Toma JG, Akhavan M, Fernandes KJ, et al. Isolation of multipotent adult stem cells from the dermis of mammalian skin. Nat cell biol 2001; 3(9): 778-84.
6. da Silva Meirelles L, Chagastelles PC, Nardi NB. Mesenchymal stem cells reside in virtually all post-natal organs and tissues. J Cell Sci 2006; 119(Pt 11): 2204-13.
7. De Ugarte DA, Morizono K, Elbarbary A, et al. Comparison of multi-lineage cells from human adipose tissue and bone marrow. Cells, tissues, organs 2003; 174(3): 101-9.
8. Campagnoli C, Roberts IA, Kumar S, Bennett PR, Bellantuono I, Fisk NM. Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood, liver, and bone marrow. Blood 2001; 98(8): 2396-402.
9. Erices A, Conget P, Minguell JJ. Mesenchymal progenitor cells in human umbilical cord blood. Brit J Haematol 2000; 109(1): 235-42.
10. In 't Anker PS, Scherjon SA, Kleijburg-van der Keur C, et al. Isolation of mesenchymal stem cells of fetal or maternal origin from human placenta. Stem Cells 2004; 22(7): 1338-45.
11. Le Blanc K, Ringden O. Mesenchymal stem cells: properties and role in clinical bone marrow transplantation. Curr opin immunol 2006; 18(5): 586-91.
12. Lodie TA, Blickarz CE, Devarakonda TJ, et al. Systematic analysis of reportedly distinct populations of multipotent bone marrow-derived stem cells reveals a lack of distinction. Tissue Eng 2002; 8(5): 739-51.
13. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8(4): 315-7.
14. Morikawa S, Mabuchi Y, Kubota Y, et al. Prospective identification, isolation, and systemic transplantation of multipotent mesen-chymal stem cells in murine bone marrow. J Exp Med 2009; 206(11): 2483-96.
15. Honczarenko M, Le Y, Swierkowski M, Ghiran I, Glodek AM, Silberstein LE. Human bone marrow stromal cells express a distinct set of biologically functional chemokine receptors. Stem Cells 2006; 24(4): 1030-41.
16. Ji JF, He BP, Dheen ST, Tay SS. Interactions of chemokines and chemokine receptors mediate the migration of mesenchymal stem cells to the impaired site in the brain after hypoglossal nerve injury. Stem Cells 2004; 22(3): 415-27.
17. Morigi M, Imberti B, Zoja C, et al. Mesenchymal stem cells are renotropic, helping to repair the kidney and improve function in acute renal failure. J Am Soc Nephrol 2004; 15(7): 1794-804.
18. Phinney DG. Biochemical heterogeneity of mesenchymal stem cell populations: clues to their therapeutic efficacy. Cell cycle (Georgetown, Tex 2007 Dec 1; 6(23): 2884-9.
19. Munoz JR, Stoutenger BR, Robinson AP, Spees JL, Prockop DJ. Human stem/progenitor cells from bone marrow promote neuro-genesis of endogenous neural stem cells in the hippocampus of mice. Proc Natl Acad Sci USA 2005; 102(50): 18171-6.
20. Herrera MB, Bussolati B, Bruno S, Fonsato V, Romanazzi GM, Camussi G. Mesenchymal stem cells contribute to the renal repair of acute tubular epithelial injury. Int J Mol Med 2004; 14(6): 1035-41.
21. Ortiz LA, Gambelli F, McBride C, et al. Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proc Natl Acad Sci USA 2003; 100(14): 8407-11.
22. Rojas M, Xu J, Woods CR, et al. Bone marrow-derived mesen-chymal stem cells in repair of the injured lung. American journal of respiratory cell and molecular biology 2005; 33(2): 145-52.
23. Muller I, Kordowich S, Holzwarth C, et al. Animal serum-free culture conditions for isolation and expansion of multipotent mes-enchymal stromal cells from human BM. Cytotherapy 2006; 8(5): 437-44.
24. Youd M, Blickarz C, Woodworth L, et al. Allogeneic mesenchy-mal stem cells do not protect NZB x NZW F(1) mice from developing lupus disease. Clin Exp Immunol 2010; 161(1): 176-86.
25. Di Nicola M, Carlo-Stella C, Magni M, et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002; 99(10): 3838-43.
26. Bartholomew A, Sturgeon C, Siatskas M, et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 2002; 30(1): 42-8.
27. Krampera M, Glennie S, Dyson J, et al. Bone marrow mesenchy-mal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 2003; 101(9): 3722-9.
28. Tse WT, Pendleton JD, Beyer WM, Egalka MC, Guinan EC. Suppression of allogeneic T-cell proliferation by human marrow stro-mal cells: implications in transplantation. Transplantation 2003; 75(3): 389-97.
29. Le Blanc K, Tammik L, Sundberg B, Haynesworth SE, Ringden O. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histo-compatibility complex. Scand J Immunol 2003; 57(1): 11-20.
30. Siegel G, Schafer R, Dazzi F. The immunosuppressive properties of mesenchymal stem cells. Transplantation 2009; 87(9 Suppl): S45-9.
31. Kim JA, Hong S, Lee B, et al. The inhibition of T-cells proliferation by mouse mesenchymal stem cells through the induction of p16INK4A-cyclin D1/cdk4 and p21waf1, p27kip1-cyclin E/cdk2 pathways. Cellular immunol 2007; 245(1): 16-23.
32. Glennie S, Soeiro I, Dyson PJ, Lam EW, Dazzi F. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood 2005; 105(7): 2821-7.
33. Newman RE, Yoo D, LeRoux MA, Danilkovitch-Miagkova A. Treatment of inflammatory diseases with mesenchymal stem cells. Inflamm Allergy Drug Targets 2009; 8(2): 110-23.
34. Jones S, Horwood N, Cope A, Dazzi F. The antiproliferative effect of mesenchymal stem cells is a fundamental property shared by all stromal cells. J Immunol 2007; 179(5): 2824-31.
35. Ramasamy R, Tong CK, Seow HF, Vidyadaran S, Dazzi F. The immunosuppressive effects of human bone marrow-derived mesen-chymal stem cells target T cell proliferation but not its effector function. Cell immunol 2008; 251(2): 131-6.
36. Ren G, Zhang L, Zhao X, et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2008; 2(2): 141-50.
37. Maccario R, Podesta M, Moretta A, et al. Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica 2005; 90(4): 516-25.
38. Ren G, Su J, Zhang L, et al. Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression. Stem cells (Dayton, Ohio) 2009; 27(8): 1954-62.
39. Bocelli-Tyndall C, Bracci L, Schaeren S, et al. Human bone marrow mesenchymal stem cells and chondrocytes promote and/or suppress the in vitro proliferation of lymphocytes stimulated by in-terleukins 2, 7 and 15. Ann Rheum Dis 2009; 68(8): 1352-9.
40. Najar M, Rouas R, Raicevic G, et al. Mesenchymal stromal cells promote or suppress the proliferation of T lymphocytes from cord blood and peripheral blood: the importance of low cell ratio and role of interleukin-6. Cytotherapy 2009; 11(5): 570-83.
41. Chan JL, Tang KC, Patel AP, et al. Antigen-presenting property of mesenchymal stem cells occurs during a narrow window at low levels of interferon-gamma. Blood 2006; 107(12): 4817-24.
42. Fang L, Lange C, Engel M, Zander AR, Fehse B. Sensitive balance of suppressing and activating effects of mesenchymal stem cells on T-cell proliferation. Transplantation 2006; 82(10): 1370-3.
43. English K, Barry FP, Field-Corbett CP, Mahon BP. IFN-gamma and TNF-alpha differentially regulate immunomodulation by mur-ine mesenchymal stem cells. Immunology letters 2007; 110(2): 91-100.
44. Sheng H, Wang Y, Jin Y, et al. A critical role of IFNgamma in priming MSC-mediated suppression of T cell proliferation through up-regulation of B7-H1. Cell research 2008; 18(8): 846-57.
45. DelaRosa O, Lombardo E, Beraza A, et al. Requirement of IFN-gamma-mediated indoleamine 2,3-dioxygenase expression in the modulation of lymphocyte proliferation by human adipose-derived stem cells. Tissue Eng Part A 2009; 15(10): 2795-806.
46. Yoo KH, Jang IK, Lee MW, et al. Comparison of immunomodula-tory properties of mesenchymal stem cells derived from adult human tissues. Cell immunol 2009; 259(2): 150-6.
47. Ryan JM, Barry F, Murphy JM, Mahon BP. Interferon-gamma does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clin Exp Immunol 2007; 149(2): 353-63.
48. Renner P, Eggenhofer E, Rosenauer A, et al. Mesenchymal stem cells require a sufficient, ongoing immune response to exert their immunosuppressive function. Transplant proc 2009; 41(6): 2607-11.
49. Meisel R, Zibert A, Laryea M, Gobel U, Daubener W, Dilloo D. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 2004; 103(12): 4619-21.
50. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005; 105(4): 1815-22.
51. Chabannes D, Hill M, Merieau E, et al. A role for heme oxygenase-1 in the immunosuppressive effect of adult rat and human mesen-chymal stem cells. Blood 2007; 110(10): 3691-4.
52. Selmani Z, Naji A, Zidi I, et al. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. Stem Cells 2008; 26(1): 212-22.
53. Augello A, Tasso R, Negrini SM, et al. Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur J Immunol 2005; 35(5): 1482-90.
54. Xue Q, Luan XY, Gu YZ, et al. The negative co-signaling molecule b7-h4 is expressed by human bone marrow-derived mesen-chymal stem cells and mediates its T-cell modulatory activity. Stem Cells Dev 2010; 19(1): 27-38.
55. Nasef A, Mathieu N, Chapel A, et al. Immunosuppressive effects of mesenchymal stem cells: involvement of HLA-G. Transplantation 2007; 84(2): 231-7.
56. Ren G, Zhang L, Zhao X, et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2008; 2: 141-50.
57. Ye Z, Wang Y, Xie HY, Zheng SS. Immunosuppressive effects of rat mesenchymal stem cells: involvement of CD4+CD25+ regulatory T cells. Hepatobiliary Pancreat Dis Int 2008; 7(6): 608-14.
58. Beyth S, Borovsky Z, Mevorach D, et al. Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood 2005; 105(5): 2214-9.
59. Lepelletier Y, Lecourt S, Arnulf B, et al. Galectin-1 and Sema-phorin-3A are two soluble factors conferring T cell immunosup-pression to bone marrow mesenchymal stem cell. Stem Cells Dev 2010; 19(7): 1075-9.
60. Nasef A, Mazurier C, Bouchet S, et al. Leukemia inhibitory factor: Role in human mesenchymal stem cells mediated immunosuppres-sion. Cell Immunol 2008; 253(1-2): 16-22.
61. Tomchuck SL, Zwezdaryk KJ, Coffelt SB, Waterman RS, Danka ES, Scandurro AB. Toll-like receptors on human mesenchymal stem cells drive their migration and immunomodulating responses. Stem Cells 2008; 26(1): 99-107.
62. Opitz CA, Litzenburger UM, Lutz C, et al. Toll-like receptor engagement enhances the immunosuppressive properties of human bone marrow-derived mesenchymal stem cells by inducing in-doleamine-2,3-dioxygenase-1 via interferon-beta and protein kinase R. Stem Cells 2009; 27(4): 909-19.
63. Liotta F, Angeli R, Cosmi L, et al. Toll-like receptors 3 and 4 are expressed by human bone marrow-derived mesenchymal stem cells and can inhibit their T-cell modulatory activity by impairing Notch signaling. Stem Cells 2008; 26(1): 279-89.
64. Di Ianni M, Del Papa B, De Ioanni M, et al. Mesenchymal cells recruit and regulate T regulatory cells. Exp Hematol 2008; 36(3): 309-18.
65. Ghannam S, Pene J, Torcy-Moquet G, Jorgensen C, Yssel H. Mes-enchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype. J Immunol 2010; 185(1): 302-12.
66. Francois M, Romieu-Mourez R, Stock-Martineau S, Boivin MN, Bramson JL, Galipeau J. Mesenchymal stromal cells cross-present soluble exogenous antigens as part of their antigen-presenting cell properties. Blood 2009; 114(13): 2632-8.
67. Zhang B, Liu R, Shi D, et al. Mesenchymal stem cells induce mature dendritic cells into a novel Jagged-2-dependent regulatory dendritic cell population. Blood 2009; 113(1): 46-57.
68. Spaggiari GM, Abdelrazik H, Becchetti F, Moretta L. MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2. Blood 2009; 113(26): 6576-83.
69. Ivanova-Todorova E, Bochev I, Mourdjeva M, et al. Adipose tissue-derived mesenchymal stem cells are more potent suppressors of dendritic cells differentiation compared to bone marrow-derived mesenchymal stem cells. Immunol lett 2009; 126(1-2): 37-42.
70. Wang Q, Sun B, Wang D, et al. Murine bone marrow mesenchy-mal stem cells cause mature dendritic cells to promote T-cell tolerance. Scand J Immunol 2008; 8(6): 607-15.
71. Djouad F, Charbonnier LM, Bouffi C, et al. Mesenchymal stem cells inhibit the differentiation of dendritic cells through an inter-leukin-6-dependent mechanism. Stem Cells 2007; 25(8): 2025-32.
72. Ramasamy R, Fazekasova H, Lam EW, Soeiro I, Lombardi G, Dazzi F. Mesenchymal stem cells inhibit dendritic cell differentiation and function by preventing entry into the cell cycle. Transplantation 2007; 83(1): 71-6.
73. Nauta AJ, Kruisselbrink AB, Lurvink E, Willemze R, Fibbe WE. Mesenchymal stem cells inhibit generation and function of both CD34+-derived and monocyte-derived dendritic cells. J Immunol 2006; 177(4): 2080-7.
74. Jiang XX, Zhang Y, Liu B, et al. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 2005; 105(10): 4120-6.
75. Jiang X-X, Zhang B, Zhang S-X, Wu Y, Yu X-D, Mao N. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 2005; 105(10): 4120-6.
76. Kim J, Hematti P. Mesenchymal stem cell-educated macrophages: a novel type of alternatively activated macrophages. Exp Hematol 2009; 37(12): 1445-53.
77. Gupta N, Su X, Popov B, Lee JW, Serikov V, Matthay MA. In-trapulmonary delivery of bone marrow-derived mesenchymal stem cells improves survival and attentuates endotoxin-induced acute lung injury in mice. J Immunol 2007; 179: 1855-63.
78. Ortiz LA, Dutreil M, Fattman C, et al. Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. Proc Natl Acad Sci USA 2007; 104(26): 11002-7.
79. Nemeth K, Leelahavanichkul A, Yuen PS, et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent re-programming of host macrophages to increase their interleukin-10 production. Nat Med 2009; 15(1): 42-9.
80. Asari S, Itakura S, Ferreri K, et al. Mesenchymal stem cells suppress B-cell terminal differentiation. Exp Hematol 2009; 37(5): 604-15.
81. Comoli P, Ginevri F, Maccario R, et al. Human mesenchymal stem cells inhibit antibody production induced in vitro by allostimula-tion. Nephrol Dial Transplant 2008; 23(4): 1196-202.
82. Rafei M, Hsieh J, Fortier S, et al. Mesenchymal stromal cell-derived CCL2 suppresses plasma cell immunoglobulin production via STAT3 inactivation and PAX5 induction. Blood 2008; 112(13): 4991-8.
83. Bochev I, Elmadjian G, Kyurkchiev D, et al. Mesenchymal stem cells from human bone marrow or adipose tissue differently modulate mitogen-stimulated B-cell immunoglobulin production in vitro. Cell Biol Intl 2008; 32(4): 384-93.
84. Corcione A, Benvenuto F, Ferretti E, et al. Human mesenchymal stem cells modulate B-cell functions. Blood 2006; 107(1): 367-72.
85. Deng W, Han Q, Liao L, You S, Deng H, Zhao RC. Effects of allogeneic bone marrow-derived mesenchymal stem cells on T and B lymphocytes from BXSB mice. DNA and cell Biol 2005; 24(7): 458-63.
86. Traggiai E, Volpi S, Schena F, et al. Bone marrow-derived mesen-chymal stem cells induce both polyclonal expansion and differentiation of B cells isolated from healthy donors and systemic lupus erythematosus patients. Stem Cells 2008; 26(2): 562-9.
87. Rasmusson I, Le Blanc K, Sundberg B, Ringden O. Mesenchymal stem cells stimulate antibody secretion in human B cells. Scandinavian journal of immunology 2007; 65(4): 336-43.
88. Cassese G, Arce S, Hauser AE, et al. Plasma cell survival is mediated by synergistic effects of cytokines and adhesion-dependent signals. J Immunol 2003; 171(4): 1684-90.
89. Spaggiari GM, Capobianco A, Abdelrazik H, Becchetti F, Mingari MC, Moretta L. Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of in-doleamine 2,3-dioxygenase and prostaglandin E2. Blood 2008; 111(3): 1327-33.
90. Spaggiari GM, Capobianco A, Becchetti S, Mingari MC, Moretta L. Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood 2006; 107(4): 1484-90.
91. Sotiropoulou PA, Perez SA, Gritzapis AD, Baxevanis CN, Papa-michail M. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells 2006; 24(1): 74-85.
92. Rasmusson I, Ringden O, Sundberg B, Le Blanc K. Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation 2003; 76(8): 1208-13.
93. Chu YW, Gress RE. Murine models of chronic graft-versus-host disease: insights and unresolved issues. Biol Blood Marrow Transplant 2008; 14(4): 365-78.
94. Reddy P, Negrin R, Hill GR. Mouse models of bone marrow transplantation. Biol Blood Marrow Transplant 2008; 14(1 Suppl 1): 129-35.
95. Toubai T, Paczesny S, Shono Y, et al. Mesenchymal stem cells for treatment and prevention of graft-versus-host disease after alloge-neic hematopoietic cell transplantation. Curr Stem Cell Res Ther 2009; 4(4): 252-9.
96. Miyashima S, Nagata N, Nakagawa T, et al. Prevention of lpr-graft-versus-host disease and transfer of autoimmune diseases in normal C57BL/6 mice by transplantation of bone marrow cells plus bones (stromal cells) from MRL/lpr mice. J Immunol 1996; 156(1): 79-84.
97. Min CK, Kim BG, Park G, Cho B, Oh IH. IL-10-transduced bone marrow mesenchymal stem cells can attenuate the severity of acute graft-versus-host disease after experimental allogeneic stem cell transplantation. Bone Marrow Transplant 2007; 39(10): 637-45.
98. Badillo AT, Peranteau WH, Heaton TE, Quinn C, Flake AW. Mur-ine bone marrow derived stromal progenitor cells fail to prevent or treat acute graft-versus-host disease. Br J Haematol 2008; 141(2): 224-34.
99. Lu X, Liu T, Gu L, et al. Immunomodulatory effects of mesen-chymal stem cells involved in favoring type 2 T cell subsets. Transplant Immunol 2009; 22(1-2): 55-61.
100. Yanez R, Lamana ML, Garcia-Castro J, Colmenero I, Ramirez M, Bueren JA. Adipose tissue-derived mesenchymal stem cells have in vivo immunosuppressive properties applicable for the control of the graft-versus-host disease. Stem Cells 2006; 24(11): 2582-91.
101. Sudres M, Norol F, Trenado A, et al. Bone marrow mesenchymal stem cells suppress lymphocyte proliferation in vitro but fail to prevent graft-versus-host disease in mice. J Immunol 2006; 176(12): 7761-7.
102. Tisato V, Naresh K, Girdlestone J, Navarrete C, Dazzi F. Mesen-chymal stem cells of cord blood origin are effective at preventing but not treating graft-versus-host disease. Leukemia 2007; 21(9): 1992-9.
103. Jeon MS, Lim HJ, Yi TG, et al. Xenoreactivity of human clonal mesenchymal stem cells in a major histocompatibility complex-matched allogeneic graft-versus-host disease mouse model. Cell Immunol 2010; 261(1): 57-63.
104. Chung NG, Jeong DC, Park SJ, et al. Cotransplantation of marrow stromal cells may prevent lethal graft-versus-host disease in major histocompatibility complex mismatched murine hematopoietic stem cell transplantation. Int J Hematol 2004; 80(4): 370-6.
105. Polchert D, Sobinsky J, Douglas G, et al. IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur J Immunol 2008; 38(6): 1745-55.
106. Joo SY, Cho KA, Jung YJ, et al. Mesenchymal stromal cells inhibit graft-versus-host disease of mice in a dose-dependent manner. Cytotherapy 2010; 12(3): 361-70.
107. Augello A, Tasso R, Negrini SM, Cancedda R, Pennesi G. Cell therapy using allogeneic bone marrow mesenchymal stem cells prevents tissue damage in collagen-induced arthritis. Arthritis Rheum 2007; 56(4): 1175-86.
108. Gonzalez MA, Gonzalez-Rey E, Rico L, Buscher D, Delgado M. Treatment of experimental arthritis by inducing immune tolerance with human adipose-derived mesenchymal stem cells. Arthritis Rheum 2009; 60(4): 1006-19.
109. Mao F, Xu WR, Qian H, et al. Immunosuppressive effects of mes-enchymal stem cells in collagen-induced mouse arthritis. Inflamm Res 2010; 59(3): 219-25.
110. Djouad F, Fritz V, Apparailly F, et al. Reversal of the immunosup-pressive properties of mesenchymal stem cells by tumor necrosis factor alpha in collagen-induced arthritis. Arthritis Rheum 2005; 52(5): 1595-603.
111. Choi JJ, Yoo SA, Park SJ, et al. Mesenchymal stem cells overex-pressing interleukin-10 attenuate collagen-induced arthritis in mice. Clin Exp Immunol 2008; 153(2): 269-76.
112. Schurgers E, Kelchtermans H, Mitera T, Geboes L, Matthys P. Discrepancy between the in vitro and in vivo effects of murine mesenchymal stem cells on T cell proliferation and collagen-induced arthritis. Arthritis Res Ther 2010; 12(1): R31.
113. Reznikoff CA, Brankow DW, Heidelberger C. Establishment and characterization of a cloned line of C3H mouse embryo cells sensitive to postconfluence inhibition of division. Cancer Res 1973; 33(12): 3231-8.
114. Tran GT, Carter N, He XY, et al. Reversal of experimental allergic encephalomyelitis with non-mitogenic, non-depleting anti-CD3 mAb therapy with a preferential effect on T(h)1 cells that is augmented by IL-4. Int Immunol 2001; 13(9): 1109-20.
115. Chung DT, Korn T, Richard J, et al. Anti-thymocyte globulin (ATG) prevents autoimmune encephalomyelitis by expanding mye-lin antigen-specific Foxp3+ regulatory T cells. Int Immunol 2007; 19(8): 1003-10.
116. Kohm AP, Williams JS, Bickford AL, et al. Treatment with nonmi-togenic anti-CD3 monoclonal antibody induces CD4+ T cell unre-sponsiveness and functional reversal of established experimental autoimmune encephalomyelitis. J Immunol 2005; 174(8): 4525-34.
117. Gold R, Linington C, Lassmann H. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 2006; 129(Pt 8): 1953-71.
118. Rafei M, Campeau PM, Aguilar-Mahecha A, et al. Mesenchymal stromal cells ameliorate experimental autoimmune encephalomye-litis by inhibiting CD4 Th17 T cells in a CC chemokine ligand 2-dependent manner. J Immunol 2009; 182(10): 5994-6002.
119. Rafei M, Birman E, Forner K, Galipeau J. Allogeneic mesenchy-mal stem cells for treatment of experimental autoimmune encepha-lomyelitis. Mol Ther 2009; 17(10): 1799-803.
120. Kassis I, Grigoriadis N, Gowda-Kurkalli B, et al. Neuroprotection and immunomodulation with mesenchymal stem cells in chronic experimental autoimmune encephalomyelitis. Arch Neurol 2008; 65(6): 753-61.
121. Gerdoni E, Gallo B, Casazza S, et al. Mesenchymal stem cells effectively modulate pathogenic immune response in experimental autoimmune encephalomyelitis. Ann Neurol 2007; 61(3): 219-27.
122. Zappia E, Casazza S, Pedemonte E, et al. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 2005; 106(5): 1755-61.
123. Bai L, Lennon DP, Eaton V, et al. Human bone marrow-derived mesenchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis. Glia 2009; 57(11): 1192-203.
124. Gordon D, Pavlovska G, Glover CP, Uney JB, Wraith D, Scolding NJ. Human mesenchymal stem cells abrogate experimental allergic encephalomyelitis after intraperitoneal injection, and with sparse CNS infiltration. Neurosci Lett 2008; 448(1): 71-3.
125. Stromnes IM, Cerretti LM, Liggitt D, Harris RA, Goverman JM. Differential regulation of central nervous system autoimmunity by T(H)1 and T(H)17 cells. Nat Med 2008; 14(3): 337-42.
126. Komiyama Y, Nakae S, Matsuki T, et al. IL-17 plays an important role in the development of experimental autoimmune encephalo-myelitis. J Immunol 2006; 177(1): 566-73.
127. Mahad DJ, Ransohoff RM. The role of MCP-1 (CCL2) and CCR2 in multiple sclerosis and experimental autoimmune encephalomye-litis (EAE). Semin Immunol 2003; 15(1): 23-32.
128. Jee Y, Yoon WK, Okura Y, Tanuma N, Matsumoto Y. Upregula-tion of monocyte chemotactic protein-1 and CC chemokine receptor 2 in the central nervous system is closely associated with relapse of autoimmune encephalomyelitis in Lewis rats. J Neuroim-munol 2002; 128(1-2): 49-57.
129. Huang DR, Wang J, Kivisakk P, Rollins BJ, Ransohoff RM. Absence of monocyte chemoattractant protein 1 in mice leads to decreased local macrophage recruitment and antigen-specific T helper cell type 1 immune response in experimental autoimmune encepha-lomyelitis. J Exp Med 2001; 193(6): 713-26.
130. Izikson L, Klein RS, Charo IF, Weiner HL, Luster AD. Resistance to experimental autoimmune encephalomyelitis in mice lacking the CC chemokine receptor (CCR)2. J Exp Med 2000; 192(7): 1075-80.
131. Woodbury D, Schwarz EJ, Prockop DJ, Black IB. Adult rat and human bone marrow stromal cells differentiate into neurons. J Neu-rosci Res 2000; 61(4): 364-70.
132. Levy YS, Merims D, Panet H, Barhum Y, Melamed E, Offen D. Induction of neuron-specific enolase promoter and neuronal markers in differentiated mouse bone marrow stromal cells. J Mol Neu-rosci 2003; 21(2): 121-32.
133. Wislet-Gendebien S, Hans G, Leprince P, Rigo JM, Moonen G, Rogister B. Plasticity of cultured mesenchymal stem cells: switch from nestin-positive to excitable neuron-like phenotype. Stem Cells 2005; 23(3): 392-402.
134. Karabatas LM, Pastorale C, de Bruno LF, et al. Early manifestations in multiple-low-dose streptozotocin-induced diabetes in mice. Pancreas 2005; 30(4): 318-24.
135. Ezquer FE, Ezquer ME, Parrau DB, Carpio D, Yanez AJ, Conget PA. Systemic administration of multipotent mesenchymal stromal cells reverts hyperglycemia and prevents nephropathy in type 1 diabetic mice. Biol Blood Marrow Transplant 2008; 14(6): 631-40.
136. Lee RH, Seo MJ, Reger RL, et al. Multipotent stromal cells from human marrow home to and promote repair of pancreatic islets and renal glomeruli in diabetic NOD/scid mice. Proc Natl Acad Sci USA 2006; 103(46): 17438-43.
137. Xie QP, Huang H, Xu B, et al. Human bone marrow mesenchymal stem cells differentiate into insulin-producing cells upon microen-vironmental manipulation in vitro. Differentiation; research in biological diversity 2009; 77(5): 483-91.
138. Chandra V, Phadnis S, Nair PD, Bhonde RR. Generation of pancreatic hormone-expressing islet-like cell aggregates from mur-ine adipose tissue-derived stem cells. Stem Cells 2009; 27(8): 1941-53.
139. Hisanaga E, Park KY, Yamada S, et al. A simple method to induce differentiation of murine bone marrow mesenchymal cells to insulin-producing cells using conophylline and betacellulin-delta4. Endocrine journal 2008; 55(3): 535-43.
140. Davani B, Ikonomou L, Raaka BM, et al. Human islet-derived precursor cells are mesenchymal stromal cells that differentiate and mature to hormone-expressing cells in vivo. Stem Cells 2007; 25(12): 3215-22.
141. Shibata T, Naruse K, Kamiya H, et al. Transplantation of bone marrow-derived mesenchymal stem cells improves diabetic poly-neuropathy in rats. Diabetes 2008; 57(11): 3099-107.
142. Kwon DS, Gao X, Liu YB, et al. Treatment with bone marrow-derived stromal cells accelerates wound healing in diabetic rats. Int Wound J 2008; 5(3): 453-63.
143. Zhang N, Li J, Luo R, Jiang J, Wang JA. Bone marrow mesenchy-mal stem cells induce angiogenesis and attenuate the remodeling of diabetic cardiomyopathy. Exp Clin Endocrinol Diabetes 2008; 116(2): 104-11.
144. Wu Y, Chen L, Scott PG, Tredget EE. Mesenchymal stem cells enhance wound healing through differentiation and angiogenesis. Stem Cells 2007; 25(10): 2648-59.
145. Urban VS, Kiss J, Kovacs J, et al. Mesenchymal stem cells cooperate with bone marrow cells in therapy of diabetes. Stem Cells 2008; 26(1): 244-53.
146. Ding Y, Xu D, Feng G, Bushell A, Muschel RJ, Wood KJ. Mesen-chymal stem cells prevent the rejection of fully allogenic islet grafts by the immunosuppressive activity of matrix metalloprotein-ase-2 and -9. Diabetes 2009; 58(8): 1797-806.
147. Solari MG, Srinivasan S, Boumaza I, et al. Marginal mass islet transplantation with autologous mesenchymal stem cells promotes long-term islet allograft survival and sustained normoglycemia. J Autoimmun 2009; 32(2): 116-24.
148. Madec AM, Mallone R, et al. Mesenchymal stem cells protect NOD mice from diabetes by inducing regulatory T cells. Diabe-tologia 2009; 52(7): 1391-9.
149. Mouiseddine M, Francois S, Semont A, et al. Human mesenchymal stem cells home specifically to radiation-injured tissues in a non-obese diabetes/severe combined immunodeficiency mouse model. Br J Radiol 2007; 80 Spec No 1: S49-55.
150. Francois S, Bensidhoum M, Mouiseddine M, et al. Local irradiation not only induces homing of human mesenchymal stem cells at exposed sites but promotes their widespread engraftment to multiple organs: a study of their quantitative distribution after irradiation damage. Stem Cells 2006; 24(4): 1020-9.
151. Fiorina P, Jurewicz M, Augello A, et al. Immunomodulatory function of bone marrow-derived mesenchymal stem cells in experimental autoimmune type 1 diabetes. J Immunol 2009; 183(2): 993-1004.
152. Emamaullee JA, Davis J, Merani S, et al. Inhibition of Th17 cells regulates autoimmune diabetes in NOD mice. Diabetes 2009; 58(6): 1302-11.
153. Jain R, Tartar DM, Gregg RK, et al. Innocuous IFNgamma induced by adjuvant-free antigen restores normoglycemia in NOD mice through inhibition of IL-17 production. J Exp Med 2008; 205(1): 207-18.
154. Nie Y, Lau CS, Lie AK, Chan GC, Mok MY. Defective phenotype of mesenchymal stem cells in patients with systemic lupus erythe-matosus. Lupus 2010 [Epub ahead of print].
155. Sun LY, Zhang HY, Feng XB, Hou YY, Lu LW, Fan LM. Abnormality of bone marrow-derived mesenchymal stem cells in patients with systemic lupus erythematosus. Lupus 2007; 16(2): 121-8.
156. Papadaki HA, Kritikos HD, Gemetzi C, et al. Bone marrow progenitor cell reserve and function and stromal cell function are defective in rheumatoid arthritis: evidence for a tumor necrosis factor alpha-mediated effect. Blood 2002; 99(5): 1610-9.
157. Papadaki HA, Boumpas DT, Gibson FM, et al. Increased apoptosis of bone marrow CD34(+) cells and impaired function of bone marrow stromal cells in patients with systemic lupus erythematosus. Br J Haematol 2001; 115(1): 167-74.
158. Shalapour S, Eckert C, Seeger K, et al. Leukemia-associated genetic aberrations in mesenchymal stem cells of children with acute lymphoblastic leukemia. J Mol Med 2010; 88(3): 249-65
159. Rubio D, Garcia-Castro J, Martin MC, et al. Spontaneous human adult stem cell transformation. Cancer research 2005; 65(8): 3035-9.
160. Miura M, Miura Y, Padilla-Nash HM, et al. Accumulated chromosomal instability in murine bone marrow mesenchymal stem cells leads to malignant transformation. Stem Cells 2006; 24(4): 1095-103.
161. Zhou YF, Bosch-Marce M, Okuyama H, et al. Spontaneous transformation of cultured mouse bone marrow-derived stromal cells. Cancer Res 2006; 66(22): 10849-54.
162. Strober W, Fuss IJ, Blumberg RS. The immunology of mucosal models of inflammation. Annu Rev Immunol 2002; 20: 495-549.
163. Zhang Q, Shi S, Liu Y, et al. Mesenchymal stem cells derived from human gingiva are capable of immunomodulatory functions and ameliorate inflammation-related tissue destruction in experimental colitis. J Immunol 2009; 183(12): 7787-98.
164. Gonzalez MA, Gonzalez-Rey E, Rico L, Buscher D, Delgado M. Adipose-derived mesenchymal stem cells alleviate experimental colitis by inhibiting inflammatory and autoimmune responses. Gastroenterology 2009; 136(3): 978-89.
165. Gonzalez-Rey E, Anderson P, Gonzalez MA, Rico L, Buscher D, Delgado M. Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis. Gut 2009; 58(7): 929-39.
166. Tanaka F, Tominaga K, Ochi M, et al. Exogenous administration of mesenchymal stem cells ameliorates dextran sulfate sodium-induced colitis via anti-inflammatory action in damaged tissue in rats. Life sciences 2008; 83(23-24): 771-9.
167. Robson MG, Walport MJ. Pathogenesis of systemic lupus erythe-matosus (SLE). Clin Exp Allergy 2001; 31(5): 678-85.
168. Sun L, Akiyama K, Zhang H, et al. Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans. Stem Cells 2009; 27(6): 1421-32.
169. Zhou K, Zhang H, Jin O, et al. Transplantation of human bone marrow mesenchymal stem cell ameliorates the autoimmune pathogenesis in MRL/lpr mice. Cell Mol Immunol 2008; 5(6): 417-24.
170. Nalbandian A, Crispin JC, Tsokos GC. Interleukin-17 and systemic lupus erythematosus: current concepts. Clin Exp Immunol 2009; 157(2): 209-15.
171. Peister A, Mellad JA, Larson BL, Hall BM, Gibson LF, Prockop DJ. Adult stem cells from bone marrow (MSCs) isolated from different strains of inbred mice vary in surface epitopes, rates of proliferation, and differentiation potential. Blood 2004; 103(5): 1662-8.
172. Izui S, Kelley VE, Masuda K, Yoshida H, Roths JB, Murphy ED. Induction of various autoantibodies by mutant gene lpr in several strains of mice. J Immunol 1984; 133(1): 227-33.
173. Horwitz EM, Prockop DJ, Fitzpatrick LA, et al. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med 1999; 5(3): 309-13.
174. Hare JM, Traverse JH, Henry TD, et al. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myo-cardial infarction. J Am Coll Cardiol 2009; 54(24): 2277-86.
175. Koc ON, Day J, Nieder M, Gerson SL, Lazarus HM, Krivit W. Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH). Bone Marrow Transplant 2002; 30(4): 215-22.
176. Maitra B, Szekely E, Gjini K, et al. Human mesenchymal stem cells support unrelated donor hematopoietic stem cells and suppress T-cell activation. Bone Marrow Transplant 2004; 33(6): 597-604.
177. Lazarus HM, Haynesworth SE, Gerson SL, Rosenthal NS, Caplan AI. Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use. Bone Marrow Transplant 1995; 16(4): 557-64.
178. Koc ON, Gerson SL, Cooper BW, et al. Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J Clin Oncol 2000; 18(2): 307-16.
179. Lazarus HM, Koc ON, Devine SM, et al. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant 2005; 11(5): 389-98.
180. Le Blanc K, Samuelsson H, Gustafsson B, et al. Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. Leukemia 2007; 21(8): 1733-8.
181. Macmillan ML, Blazar BR, DeFor TE, Wagner JE. Transplantation of ex-vivo culture-expanded parental haploidentical mesenchymal stem cells to promote engraftment in pediatric recipients of unrelated donor umbilical cord blood: results of a phase I-II clinical trial. Bone Marrow Transplant 2009; 43(6): 447-54.
182. Le Blanc K, Rasmusson I, Sundberg B, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mes-enchymal stem cells. Lancet 2004; 363(9419): 1439-41.
183. Ringdén O, Uzunel M, Rasmusson I, et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006; 81(10): 1390-7.
184. Le Blanc K, Frassoni F, Ball L, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008; 371(9624): 1579-86.
185. von Bonin M, Stolzel F, Goedecke A, et al. Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium. Bone Marrow Transplant 2009; 43(3): 245-51.
186. Kebriaei P, Isola L, Bahceci E, et al. Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease. Biol Blood Marrow Transplant 2009; 15(7): 804-11.
187. MacMillan ML, Weisdorf DJ, Wagner JE, et al. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems. Biol Blood Marrow Transplant 2002; 8(7): 387-94.
188. Levine JE, Paczesny S, Mineishi S, et al. Etanercept plus methyl-prednisolone as initial therapy for acute graft-versus-host disease. Blood 2008; 111(4): 2470-5.
189. Martin PJ, Uberti JP, Soiffer RJ, et al. Prochymal improves response rates in patients with steroid-refactory acute graft versus host disease (SR-GVHD) involving the liver and gut: results of a randomized, placebo-controlled, multicenter phase III trial in GVHD. TANDEM Abstract #41. 2010.
190. Szabolcs P, Visani G, Locatelli F, et al. Treatment of steroid-refractory acute GVHD with mesenchymal stem cells improves outcomes in perdiatric patients; results of the prediatric subset in a phase III randomized, placebo-controlled study. TANDEM Abstract #381. 2010.
191. ®) as a rescue agent for severe treatment resistant GVHD in pediatric patients. TANDEM Abstract #40. 2010.
192. ® adult mesenchymal stem cells in Crohn's disease. Gastroenterology 2008; 134: A-661.
193. Tyndall A, Uccelli A. Multipotent mesenchymal stromal cells for autoimmune diseases: teaching new dogs old tricks. Bone Marrow Transplant 2009; 43(11): 821-8.
194. Karussis D, Kassis I, Kurkalli BG, Slavin S. Immunomodulation and neuroprotection with mesenchymal bone marrow stem cells (MSCs): a proposed treatment for multiple sclerosis and other neu-roimmunological/neurodegenerative diseases. J Neurol Sci 2008; 265(1-2): 131-5.
195. Freedman MS, Bar-Or A, Atkins HL, et al. The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group. Mult Scler 2010; 16(4): 503-10.
196. Mohyeddin Bonab M, Yazdanbakhsh S, Lotfi J, et al. Does mesen-chymal stem cell therapy help multiple sclerosis patients? Report of a pilot study. Iran J Immunol 2007; 4(1): 50-7.
197. Nauta AJ, Fibbe WE. Immunomodulatory properties of mesen-chymal stromal cells. Blood 2007; 110(10): 3499-506.
198. Carrion F, Nova E, Ruiz C, et al. Autologous mesenchymal stem cell treatment increased T regulatory cells with no effect on disease activity in two systemic lupus erythematosus patients. Lupus 2010; 19(3): 317-22.
199. Sun L, Wang D, Liang J, et al. Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythe-matosus. Arthritis Rheum 2010; 62(8): 2467-75.